J 2021

Prevalence of COVID-19 Vaccine Side Effects among Healthcare Workers in the Czech Republic

RIAD, Abanoub, Andrea POKORNÁ, Sameh ATTIA, Jitka KLUGAROVÁ, Michal KOŠČÍK et. al.

Základní údaje

Originální název

Prevalence of COVID-19 Vaccine Side Effects among Healthcare Workers in the Czech Republic

Autoři

RIAD, Abanoub (818 Egypt, garant, domácí), Andrea POKORNÁ (203 Česká republika, domácí), Sameh ATTIA, Jitka KLUGAROVÁ (203 Česká republika, domácí), Michal KOŠČÍK (203 Česká republika, domácí) a Miloslav KLUGAR (203 Česká republika, domácí)

Vydání

Journal of Clinical Medicine, Basel, MDPI, 2021, 2077-0383

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30218 General and internal medicine

Stát vydavatele

Švýcarsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

Impakt faktor

Impact factor: 4.964

Kód RIV

RIV/00216224:14110/21:00121325

Organizační jednotka

Lékařská fakulta

DOI

UT WoS

000638607800001

Klíčová slova anglicky

adverse effects; BNT162 vaccine; cross-sectional studies; COVID-19; Czech Republic; drug-related side effects and adverse reactions; health personnel; mass vaccination; prevalence

Štítky

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 17. 5. 2022 08:58, Mgr. Tereza Miškechová

Anotace

V originále

Background: COVID-19 vaccine side effects have a fundamental role in public confidence in the vaccine and its uptake process. Thus far, the evidence on vaccine safety has exclusively been obtained from the manufacturer-sponsored studies; therefore, this study was designed to provide independent evidence on Pfizer–BioNTech COVID-19 vaccine side effects. Methods: A cross-sectional survey-based study was carried out between January and February 2021 to collect data on the side effects following the COVID-19 vaccine among healthcare workers in the Czech Republic. The study used a validated questionnaire with twenty-eight multiple-choice items covering the participants’ demographic data, medical anamneses, COVID-19-related anamneses, general, oral, and skin-related side effects. Results: Injection site pain (89.8%), fatigue (62.2%), headache (45.6%), muscle pain (37.1%), and chills (33.9%) were the most commonly reported side effects. All the general side effects were more prevalent among the ≤43-year-old group, and their duration was mainly one day (45.1%) or three days (35.8%) following the vaccine. Antihistamines were the most common drugs associated with side effects, thus requiring further investigation. The people with two doses were generally associated with a higher frequency of side effects. Conclusions: The distribution of side effects among Czech healthcare workers was highly consistent with the manufacturer’s data, especially in terms of their association with the younger age group and the second dose. The overall prevalence of some local and systemic side effects was higher than the manufacturer’s report. Further independent studies on vaccine safety are strongly required to strengthen public confidence in the vaccine.

Návaznosti

CZ.02.1.01/0.0/0.0/16_013/0001826, interní kód MU
(Kód CEP: EF16_013/0001826)
Název: CZECRIN_PRO PACIENTY - zavádění inovativních moderních terapií
Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, CZECRIN_PRO PACIENTY - zavádění inovativních moderních terapií, PO 1 Posilování kapacit pro kvalitní výzkum
LTC20031, projekt VaV
Název: Towards an International Network for Evidence-based Research in Clinical Health Research in the Czech Republic
Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, Towards an International Network for Evidence-based Research in Clinical Health Research in the Czech Republic, INTER-COST
MUNI/A/1608/2020, interní kód MU
Název: Prohlubování znalostí v oblasti zdravotních rizik a benefitů výživy, prostředí a životního stylu III
Investor: Masarykova univerzita, Prohlubování znalostí v oblasti zdravotních rizik a benefitů výživy, prostředí a životního stylu III
MUNI/IGA/1543/2020, interní kód MU
Název: Evidence-based Practice of Healthcare Professionals and Students in the Czech Republic (Akronym: Evidence-Based Practice in Czechia)
Investor: Masarykova univerzita, Evidence-based Practice of Healthcare Professionals and Students in the Czech Republic
90128, velká výzkumná infrastruktura
Název: CZECRIN III